RE-AGN 2.0 is a proprietary immuno-oncology therapy being developed to address lung and liver cancers.
• Enhanced targeting with longer persistence
• Combination NK cells and DCs for dual mode of action
• NK cells in combination with novel checkpoint antibodies
• NK cells in combination with targeted therapy and chemotherapy